Enanta Pharmaceuticals Files 8-K Report

TL;DR

ENANTA files 8-K, check for updates.

AI Summary

On September 29, 2025, Enanta Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statements and exhibits. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing indicates Enanta Pharmaceuticals is providing updates to the SEC, which could include important operational or financial information for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural report without immediate disclosure of significant negative or positive events.

Key Players & Entities

• ENANTA PHARMACEUTICALS, INC. (company) — Registrant
• September 29, 2025 (date) — Date of earliest event reported
• 4 Kingsbury Avenue Watertown, Massachusetts 02472 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select

Filing Documents

• d16388d8k.htm (8-K) — 37KB
• d16388dex991.htm (EX-99.1) — 29KB
• g16388g0927051515200.jpg (GRAPHIC) — 4KB
• 0001193125-25-221527.txt ( ) — 194KB
• enta-20250929.xsd (EX-101.SCH) — 3KB
• enta-20250929_lab.xml (EX-101.LAB) — 17KB
• enta-20250929_pre.xml (EX-101.PRE) — 11KB
• d16388d8k_htm.xml (XML) — 3KB

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K includes forward-looking statements, including with respect to the prospects for further development and advancement of zelicapavir for the treatment of RSV. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this report are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage discovery efforts in the disease areas in Enanta's research and development pipeline, such as RSV; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV; Enanta's limited clinical development experience; Enanta's need to attract and retain senior management and key scientific personnel; Enanta's need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in "Risk Factors" in Enanta's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this report. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circu

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated September 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 29, 2025 ENANTA PHARMACEUTICALS, INC. By: /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR